We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Findings May Spur Development of Drugs to Treat Brain Tumors in Infants

By LabMedica International staff writers
Posted on 09 Nov 2009
Efforts to develop drugs to treat a benign form of pediatric brain tumor may be facilitated by the discovery of a mutation linked to the sporadic development of such tumors. More...


The growth of benign pilocytic astrocytomas in small children often occurs in the context of neurofibromatosis 1 (NF1), an inherited condition that is one of the most common tumor predisposition syndromes, as well as arising spontaneously without connection to NF1. Conditions caused by these tumors include headache, nausea, vomiting, problems with balance, and visual impairment.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) performed detailed genetic and genomic analyses of tumor samples from 70 patients with sporadic pilocytic astrocytomas and nine patients with NF1. They reported in the September 30, 2009, online edition of the journal Neurology that 42 of the 70 patients with sporadic pilocytic astrocytomas had alterations in the BRAF gene, while none of the NF1 patients did.

The protein encoded by the BRAF gene plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene have been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small-cell lung carcinoma, and lung adenocarcinoma.

"BRAF was a particularly enticing target because the signaling pathway that it controls is also controlled by neurofibromin, the protein made by the gene that is mutated in patients with NF1," explained senior author Dr. David H. Gutmann, professor of neurology at the Washington University School of Medicine. "This finding is exciting, since a number of drugs are known to inhibit this pathway, some of which are already being tested for their ability to control the growth of other cancers. Now that we understand the signature mutation in these common pediatric tumors, we can think about designing treatments that alter the pathway that gene controls. That is important because right now we have few treatments tailored to this tumor type."

Related Links:
Washington University School of Medicine



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Thyroid Test
Anti-Thyroid EIA Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.